Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases

Objective: Infantile cephalic and facial hemangiomas (IHs) are common and histologically benign vascular lesions in infants. This study investigates the clinical effect of using large doses of Propranolol for the treatment of IHs. Study design: This study contains 38 patients with IHs. All patients received general screening before the treatment. The dosage of Propranolol was increased over the course of treatment, which initiated three days. 1mg/kg on the first day, then increased by 0.5 mg/kg each day. The daily dose was divided into two smaller doses, administered every 12 hours, half an hour after feeding. Patients were hospitalized for six days. In the absence of side effects, treatment was continued at home and patients were reevaluated every month. Generally, one course of treatment lasted six months. Results: With the treatment, the entire group had significant improvement. 6 of them had excellent results. 22 had a good response with considerable lesion reduction. Side effects were limited during or after the treatment. Conclusions: Large doses of oral Propranolol to treat severe IHs patients had great clinical results. The treatment can shorten the natural course of IHs, making it a possible first choice for treatment.

Infantile hemangiomas; Propranolol

1. K.E. Holland, B.A. Drolet, Infantile hemangioma, Pedi Clin North Am, 57 1069-1083, 2010.

2. F. Blei, D.B. McElhinney, A. Guarini, S. Presti, Cardiac Screening in Infants with Infantile Hemangiomas before Propranolol Treatment, Pediatric dermatology, 2014.

3. C. Leaute-Labreze, E. Dumas de la Roque, T. Hubiche, F. Boralevi, J.B. Thambo, A. Taieb, Propranolol for severe hemangiomas of infancy, N Engl J Med, 358, 2649-2651. 2008.

4. V. Sans, E.D. de la Roque, J. Berge, N. Grenier, F. Boralevi, J. Mazereeuw- Hautier, D. Lipsker, E. Dupuis, K. Ezzedine, P. Vergnes, A. Taieb, C. Leaute-Labreze, Propranolol for severe infantile hemangiomas: follow-up report, Pediat, 124, e423-431.2009.

5. A.L. Bruckner, I.J. Frieden, Infantile hemangiomas, Journal of the American Academy of Dermatology, 55 671-682,2006.

6. A.N. Haggstrom, E.J. Lammer, R.A. Schneider, R. Marcucio, I.J. Frieden, Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development, Pediatrics, 117, 698-703, 2006.

7 O. Enjolras, F. Gelbert, Superficial hemangiomas: associations and management, Pediatric dermatology, 14 173-179, 1997.

8. M.L. Bennett, A.B. Fleischer, Jr., S.L. Chamlin, I.J. Frieden, Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation, Archives of dermatology, 137, 1208-1213. 2001.

9. M.E. George, V. Sharma, J. Jacobson, S. Simon, A.J. Nopper, Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas, Arch Dermatol, 140, 963-969. 2004.

10. F. Denoyelle, N. Leboulanger, O. Enjolras, R. Harris, G. Roger, E.N. Garabedian, Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma, Int J Ped otorhinolaryngol, 73,,1168-1172. 2009.

11. Y. Ji, S. Chen, K. Li, X. Xiao, S. Zheng, T. Xu, The role of beta-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells, Cell Div, 8, 1. 2013.

12. C.H. Storch, P.H. Hoeger, Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action, Brit J Dermatol, 163, 269-274. 2010.

13. A.A. Talaat, M.S. Elbasiouny, D.S. Elgendy, T.F. Elwakil, Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations, J Pediat Surg, 47,707-714. 2012.

14. H. Shashidhar, N. Langhans, R.J. Grand, Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study, J Pediat Gastroent and Nut, 29 12-17. 1999.

15. E.C. Siegfried, W.J. Keenan, S. Al-Jureidini, More on propranolol for hemangiomas of infancy, N Engl J Med, 359, 2846; author reply 2846- 2847. 2008.

16. J.N. Love, N. Sikka, Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers, The J Emerg Med, 26, 309-314. 2004.

17. R.F. Centeno, Y.L. Yu, The propanolol-epinephrine interaction revisited: a serious and potentially catastrophic adverse drug interaction in facial plastic surgery, Plast Reconstr Surg, 111,944-945. 2003.

18. C.A. Foster, S.J. Aston, Propranolol-epinephrine interaction: a potential disaster, Plast Reconstr Surg, 72 ,74-78. 1983.

19. W.R. Hiatt, E.E. Wolfel, S. Stoll, A.S. Nies, G.O. Zerbe, H.L. Brammell, L.D. Horwitz, beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol, Clin Pharmacol and Therap, 37 ,2-6. 1985.